Le Lézard
Classified in: Health
Subjects: CCA, TDS, FVT

Insmed to Present at Three September Conferences


BRIDGEWATER, N.J., Sept. 9, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following virtual investor conferences:

Each presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. Each webcast will be archived for a period of 30 days following the conclusion of each live event.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product, ARIKAYCE® (amikacin liposome inhalation suspension), is the first and only therapy approved in the United States for the treatment of refractory Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a chronic, debilitating condition that can cause severe and permanent lung damage. Insmed is also advancing brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in bronchiectasis and other inflammatory diseases, and treprostinil palmitil, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.

Contact:

Investors:
Argot Partners
Laura Perry or Heather Savelle
(212) 600-1902
[email protected] 

Media:
Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
[email protected]

(PRNewsfoto/Insmed Incorporated)

 

SOURCE Insmed Incorporated


These press releases may also interest you

at 13:00
Starting next week, the Network of National Library of Medicine and Columbus Metropolitan Library in Columbus, OH will host the All of Us Journey. This traveling educational exhibit brings the National Institutes of Health's All of Us Research...

at 13:00
$56.5M Equity Financing Led by Questa Capital, Laerdal Million Lives Fund, and Catalyst Health Ventures, with New Participation from RC Capital and Eckuity CapitalAvive has rapidly built an expansive and diverse customer base, delivering its FDA...

at 13:00
Lynx Dx, a leader in innovative diagnostic solutions, hailed new peer-reviewed research published today in the Journal of the American Medical Association (JAMA) Oncology that validates the efficacy of MyProstateScore 2.0 (MPS2), the company's...

at 12:50
Data infrastructure and analytics company Kalderos, Inc., today announced that on Tuesday, April 16, it asked the Eighth Circuit for leave to file an amicus brief in support of Pharmaceutical Research and Manufacturers of America's (PhRMA's) petition...

at 12:20
Titan CEO and headline sponsor Wipfli LLP are pleased to announce Judith Nowlin, CEO of Nest Collaborative as a 2024 Colorado Titan 100. The Titan 100 program recognizes Colorado's Top 100 CEOs & C-level executives. They are the area's most...

at 12:18
Memorial Healthcare System and Solis Mammography, are pleased to announce the opening of the collaboration's first community-based breast screening centers in Weston, Plantation and Hialeah, Florida. The centers represent the commitment that both...



News published on and distributed by: